CEO and Fund Manager, Renaissance Venture Capital Fund
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Nobel Laureate, Professor of Biology, Caltech
All new chemical entities entering clinical development still require improvements in synthesis and formulation to become commercially viable, a process that can require a sizable investment. Partnering with a contract research organization (CRO) to deliver an innovative manufacturing process can be a strategic way to maximize the sponsor’s resources. Biocom has invited speakers from DavosPharma, Velesco Pharmaceutical Services, Cadence Pharmaceuticals, and Advantar Laboratories to offer their perspectives on innovating in outsourced projects. More information and online registration is available here.